GlassScriptPhysician profile
Ghazal Ahmad
NPI 1366019622
$2,860.82
in general payments reported to CMS, 2019-2025
25 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.52 · 2022: $259 · 2023: $932 · 2024: $878 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $683.12 | 2022-2025 | Briviact, Zilbrysq, Fintepla |
| Abbvie INC. | $598.21 | 2023-2025 | Qulipta, Ubrelvy |
| Jazz Pharmaceuticals INC. | $243.67 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $234.52 | 2023-2025 | Soliris, Ultomiris |
| Sk Life Science, INC. | $164.27 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $138.49 | 2023-2024 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $130.53 | 2023-2024 | |
| Csl Behring | $112.55 | 2025 | Hizentra |
| Tg Therapeutics, INC. | $112.20 | 2023 | |
| Biogen, INC. | $53.70 | 2023-2025 | Skyclarys, Skyclarys |
| Amgen INC. | $52.30 | 2024 | Uplizna |
| Livanova USA, INC. | $35.59 | 2022-2025 | Vns Therapy |
| Argenx US, INC. | $33.22 | 2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $30.10 | 2025 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $29.77 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $28.99 | 2023 | |
| Merz Pharmaceuticals, LLC | $24.83 | 2024 | Xeomin |
| Itf Therapeutics LLC | $24.10 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.97 | 2023 | |
| Biocodex, INC. | $21.50 | 2024 | |
| Nevro Corp. | $19.98 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.69 | 2024 | Zonisade |
| Genzyme Corporation | $17.38 | 2021 | |
| Pfizer INC. | $15.70 | 2021 | |
| Currax Pharmaceuticals LLC | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazal Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.